Long-Term Outcome Trajectories Following Coronary Microvascular Dysfunction

Abstract

Coronary microvascular dysfunction (CMD) is increasingly recognized as a significant contributor to myocardial ischemia and adverse cardiovascular outcomes in both women and men. Despite the absence of obstructive coronary artery disease, patients with CMD experience persistent symptoms, elevated risk of major adverse cardiovascular events (MACE), and reduced quality of life. This article provides a comprehensive review of the long-term outcome trajectories associated with CMD, highlighting epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, current management strategies, as well as recent advances and guideline recommendations. Emphasizing the clinical significance of CMD, this review integrates recent evidence and expert perspectives to inform optimal patient care and future research priorities.

Introduction

Coronary microvascular dysfunction, characterized by impaired regulation of myocardial blood flow in the absence of epicardial coronary artery obstruction, represents a complex and underappreciated entity. CMD is implicated in a substantial proportion of patients with angina or ischemia with non-obstructive coronary arteries (INOCA), posing diagnostic and therapeutic challenges. Long-term outcomes in CMD are increasingly recognized as clinically relevant, as ongoing symptoms and heightened cardiovascular risk persist despite traditional therapies. Understanding the multidimensional trajectory of CMD is essential for clinicians managing this heterogeneous patient population, and recent advances in pathophysiology, diagnostics, and therapeutics necessitate a contemporary review.

Epidemiology / Disease Burden

CMD is prevalent in up to 50% of patients undergoing coronary angiography for chest pain without obstructive disease, with a female preponderance. Large cohort studies, such as the Women’s Ischemia Syndrome Evaluation (WISE), have demonstrated that patients with CMD face a two- to four-fold increased risk of MACE compared to matched controls. The disease burden extends beyond cardiovascular endpoints, encompassing frequent hospitalizations, impaired functional status, and substantial healthcare utilization. Notably, CMD is now recognized as an independent risk factor for heart failure with preserved ejection fraction (HFpEF), further amplifying its long-term impact.

Pathophysiology

The pathophysiology of CMD is multifactorial, involving both structural and functional abnormalities of the coronary microcirculation. Endothelial dysfunction, impaired vasodilation, microvascular remodeling, and increased vascular resistance collectively impair myocardial perfusion. Inflammation, oxidative stress, and neurohormonal dysregulation further exacerbate microvascular impairment, while emerging evidence implicates alterations in perivascular adipose tissue and extracellular matrix remodeling in disease progression. Genetic predisposition and comorbidities such as diabetes, hypertension, and dyslipidemia modulate the risk and severity of CMD, underscoring the need for a mechanism-based approach to management.

Risk Factors

Several risk factors are associated with CMD, including traditional cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia, smoking), female sex, obesity, metabolic syndrome, and chronic inflammatory states. Notably, CMD is more prevalent in postmenopausal women, likely reflecting hormonal and endothelial changes. Psychosocial stress, autoimmune diseases, and microvascular rarefaction in chronic kidney disease are additional contributors. The interplay between genetic, environmental, and metabolic risk determinants shapes individual trajectories, highlighting the importance of comprehensive risk assessment in clinical practice.

Clinical Features

Patients with CMD typically present with exertional or rest angina, exertional dyspnea, or atypical chest discomfort. Importantly, symptoms may persist despite normal or near-normal findings on coronary angiography, creating diagnostic uncertainty. Recurrent, unexplained hospitalizations for chest pain are common, and chronic symptoms can lead to reduced physical activity, anxiety, and depression. In some cases, CMD manifests as acute coronary syndromes with non-obstructive coronary arteries (MINOCA) or contributes to the development of HFpEF, further complicating the clinical picture.

Diagnosis

Diagnosis of CMD requires a high index of suspicion and is often established through assessment of coronary flow reserve (CFR) or microvascular resistance using invasive (e.g., intracoronary Doppler flow wire, thermodilution) or non-invasive (e.g., positron emission tomography [PET], cardiac magnetic resonance imaging [CMR]) modalities. Endothelial function testing (e.g., acetylcholine provocation) and advanced imaging can provide mechanistic insights. Contemporary guidelines emphasize the importance of distinguishing CMD from epicardial coronary disease and other causes of chest pain, advocating for tailored diagnostic algorithms that incorporate patient phenotype and comorbidities.

Treatment & Management

Management of CMD is multifaceted, focusing on symptom relief, risk factor modification, and improvement of long-term outcomes. Anti-anginal agents such as beta-blockers, calcium channel blockers, and nitrates may provide symptomatic benefit, though evidence for outcome improvement is limited. Statins, renin-angiotensin-aldosterone system (RAAS) inhibitors, and lifestyle interventions targeting physical activity, weight reduction, and glycemic control are recommended for risk modification. Psychosocial support and cardiac rehabilitation are increasingly recognized as essential components of comprehensive care. Individualized management plans, informed by phenotypic and mechanistic profiling, are critical for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances in CMD research have expanded the therapeutic landscape. Pharmacologic agents targeting endothelial dysfunction (e.g., ranolazine, ACE inhibitors), anti-inflammatory therapies, and SGLT2 inhibitors have shown promise in selected populations. Novel non-pharmacologic strategies, including coronary sinus reducers and neuromodulation, are under investigation. Advances in imaging and molecular diagnostics enable earlier detection and mechanistic stratification, facilitating precision medicine approaches. Ongoing clinical trials and registries are expected to further clarify the role of emerging therapies in long-term outcome modification.

Guideline Recommendations

Contemporary guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) emphasize the importance of recognizing CMD as a distinct clinical entity. Recommendations include routine assessment for CMD in patients with angina and non-obstructive coronary arteries, comprehensive risk factor management, and consideration of both pharmacologic and non-pharmacologic therapies. Shared decision-making, patient education, and multidisciplinary care are highlighted as best practices for optimizing patient-centered outcomes.

Conclusion

Coronary microvascular dysfunction represents a prevalent and clinically significant condition with adverse long-term outcome trajectories. Persistent symptoms, elevated risk of MACE, and association with HFpEF underscore the need for heightened clinical awareness and evidence-based management. Advances in mechanistic understanding, diagnostics, and therapeutics hold promise for improving prognosis and quality of life in this challenging population. Ongoing research and integration of guideline-directed care are imperative to address the unmet needs of patients with CMD and to refine long-term management strategies.